Eli Lilly (LLY) earnings Q2 2026

Key Points:

• Eli Lilly reported second-quarter earnings and revenue that exceeded estimates, driven by strong demand for its weight loss drug Zepbound and diabetes treatment Mounjaro, leading to an increased full-year sales forecast of $85 billion to $87 billion for 2026.
• The company posted adjusted earnings per share of $8.38, surpassing the expected $6.01, and revenue of $22.97 billion versus the anticipated $20.73 billion, with U.S. revenue rising 33% and international revenue up 80%.
• Mounjaro's worldwide sales surged 91% to $9.94 billion, including a 172% increase outside the U.S., while Zepbound generated $4.93 billion in U.S. revenue, up 44% year-over-year despite lower prices due to discounts.
• Lilly's newly launched obesity pill, Foundayo, reported $98 million in second-quarter sales, slightly below analyst expectations, marking its first earnings contribution amid competition from Novo Nordisk's oral GLP-1 drug.
• The company is leveraging its strong financial performance to pursue a historic M&A spree, including recent acquisitions in psychedelics and vaccines, while anticipating increased prescription volumes fueled by lower prices and new Medicare coverage for obesity drugs.